July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Aakash Desai Shares Review on HER2-Altered NSCLC and Emerging Targeted Strategies
Jun 20, 2025, 10:15

Aakash Desai Shares Review on HER2-Altered NSCLC and Emerging Targeted Strategies

Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn:

“Excited to share our recent review in Frontiers in exploring the evolving landscape of HER2-altered non-small cell lung cancer (NSCLC).

HER2 is no longer just a breast cancer story — it’s an emerging, actionable driver in lung adenocarcinoma, particularly among never-smokers.

In this review, we cover:

  • Molecular biology of HER2 mutations, amplification and overexpression
  • FDA-approved diagnostics with tissue and ctDNA testing and response monitoring
  • Treatment strategies including T-DXd, zongertinib, ARX788, and more
  • Ongoing trials exploring ADCs, TKIs, & combination regimens.”

Title: HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities

Authors: Ahmed Ismail, Yanis Boumber, Aakash Desai

Read The Full Article at Frontiers.

Aakash Desai Shares Review on HER2-Altered NSCLC and Emerging Targeted Strategies

More posts featuring Aakash Desai on OncoDaily.